What is the value of real-world evidence in addressing practical questions related to the use of CGRP pathway mAbs?

While randomised controlled trials (RCTs) have traditionally been the evidentiary standard for determining market authorisations, real-world studies have become increasingly important in providing complementary clinical evidence for several stakeholders, including regulatory and technology assessment authorities.^1,2 Read the article below to learn more about the value of real-world e